24 October 2014, 7:20 am
AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 earlier this month in Philadelphia, United States. Serious side-effects were uncommon and few people discontinued treatment for this reason. Direct-acting antiviral agents have brought about a revolution in


23 October 2014, 8:00 am
Though there has been improving performance of healthcare delivery at each point of the HIV care cascade, from linkage to care through viral suppression, "success varies significantly by age and gender, even in an integrated care system with equal access to care,” Michael Horberg of the Mid-Atlantic Permanente Research Institute reported earlier this month at


23 October 2014, 7:10 am
While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialised countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in


22 October 2014, 8:00 am
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 earlier this month in Philadelphia, United States. A related study shed light on factors affecting choice of initial antiretroviral regimen.


21 October 2014, 8:50 am
Three quarters of infants starting antiretroviral therapy (ART) across eleven clinics in southern Africa had severe HIV disease and 87.2% met the 2006 World Health Organization (WHO) definition of severe immunosuppression, according to a study presented at the 2014 Southern African HIV Clinicians Society conference in Cape Town, South Africa, last month. There was a modest improvement


1 2
LATEST VIDEOS

TAKE ACTION
UPCOMING EVENTS
    • No upcoming events
  • YOUR NEWS
  • View All Add your news
    YOUR PICTURES
  • LATEST TWEETS